Improved glucose metabolism in vitro and in vivo by an allosteric monoclonal antibody that increases insulin receptor binding affinity

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Corbin, John A ^a   Bhaskar, Vinay ^a   Goldfine, Ira D ^b   Bedinger, Daniel H ^a   Lau, Angela ^a   Michelson, Kristen ^a   Gross, Lisa M ^a   Maddux, Betty A ^b   Kuan, Hua F ^a   Tran, Catarina ^a   Lao, Llewelyn ^a   Handa, Masahisa ^a   Watson, Susan R ^a   Narasimha, Ajay J ^a   Zhu, Shirley ^a   Levy, Raphael ^a   Webster, Lynn ^a   Wijesuriya, Sujeewa D ^a   Liu, Naichi ^a   Wu, Xiaorong ^a   Chemla Vogel, David ^a   Lee, Steve R ^a   Wong, Steve ^a   Wilcock, Diane ^a   White, Mark L ^a   more..

^a XOMA Corporation   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN RECEPTOR; MONOCLONAL ANTIBODY; SOMATOMEDIN C; UNCLASSIFIED DRUG; XMETS ANTIBODY; INSR PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PEPTIDE LIBRARY;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHOSPHORYLATION; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN BINDING; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; INTRACELLULAR SIGNALING; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ANIMAL; BINDING SITE; C57BL MOUSE; CELL SEPARATION; CHEMISTRY; CHO CELL LINE; CRICETULUS; FLOW CYTOMETRY; HAMSTER; HYPERINSULINISM; METABOLISM; OBESITY; PEPTIDE LIBRARY; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

ALLOSTERIC SITE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; C-PEPTIDE; CELL SEPARATION; CHO CELLS; CRICETINAE; CRICETULUS; DIABETES MELLITUS, TYPE 2; FLOW CYTOMETRY; GLUCOSE; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; MICE; MICE, INBRED C57BL; OBESITY; PEPTIDE LIBRARY; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 84895737225     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088684     Document Type: Article

References (59)

1. Ussar S, Vienberg SG, Kahn CR (2011) Receptor antibodies as novel therapeutics for diabetes. Sci Transl Med 3: 113ps147.
2. Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7: 85-96. (Pubitemid 43278292)
3. Goldfine ID, Roth RA (1986) Monoclonal antibodies to the insulin receptor as probes of insulin receptor structure and function. Horiz Biochem Biophys 8: 471-502.
4. Soos MA, Siddle K, Baron MD, Heward JM, Luzio JP, et al. (1986) Monoclonal antibodies reacting with multiple epitopes on the human insulin receptor. Biochem J 235: 199-208. (Pubitemid 16041992)
5. Siddle K, Soos MA, O'Brien RM, Ganderton RH, Taylor R (1987) Monoclonal antibodies as probes of the structure and function of insulin receptors. Biochem Soc Trans 15: 47-51. (Pubitemid 17010253)
6. Lupsa BC, Chong AY, Cochran EK, Soos MA, Semple RK, et al. (2009) Autoimmune forms of hypoglycemia. Medicine (Baltimore) 88: 141-153.
7. Le Marchand-Brustel Y, Gorden P, Flier JS, Kahn CR, Freychet P (1978) Anti-insulin receptor antibodies inhibit insulin binding and stimulate glucose metabolism in skeletal muscle. Diabetologia 14: 311-317. (Pubitemid 8321892)
8. De Pirro R, Roth RA, Rossetti L, Goldfine ID (1984) Characterization of the serum from a patient with insulin resistance and hypoglycemia. Evidence for multiple populations of insulin receptor antibodies with different receptor binding and insulin-mimicking activities. Diabetes 33: 301-304. (Pubitemid 14196224)
9. Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, et al. (2002) Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) 81: 87-100. (Pubitemid 34218566)
10. Zick Y, Rees-Jones RW, Taylor SI, Gorden P, Roth J (1984) The role of antireceptor antibodies in stimulating phosphorylation of the insulin receptor. J Biol Chem 259: 4396-4400. (Pubitemid 14127804)
11. Kahn CR, Baird K, Filier JS, Jarrett DB (1977) Effects of autoantibodies to the insulin receptor on isolated adipocytes. Studies of insulin binding and insulin action. J Clin Invest 60: 1094-1106. (Pubitemid 8223136)
12. Kahn CR, Baird KL, Jarrett DB, Flier JS (1978) Direct demonstration that receptor crosslinking or aggregation is important in insulin action. Proc Natl Acad Sci U S A 75: 4209-4213. (Pubitemid 9025979)
13. Flier JS, Kahn CR, Roth J, Bar RS (1975) Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance. Science 190: 63-65.
14. Brunetti A, Maddux BA, Wong KY, Hofmann C, Whittaker J, et al. (1989) Monoclonal antibodies to the human insulin receptor mimic a spectrum of biological effects in transfected 3T3/HIR fibroblasts without activating receptor kinase. Biochem Biophys Res Commun 165: 212-218. (Pubitemid 20012477)
15. Koschubs T, Dengl S, Durr H, Kaluza K, Georges G, et al. (2012) Allosteric antibody inhibition of human hepsin protease. Biochem J 442: 483-494.
16. Cazorla M, Arrang JM, Premont J (2011) Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor. Br J Pharmacol 162: 947-960.
17. Hino T, Arakawa T, Iwanari H, Yurugi-Kobayashi T, Ikeda-Suno C, et al. (2012) G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody. Nature 482: 237-240.
18. Bhaskar V, Goldfine ID, Bedinger DH, Lau A, Kuan HF, et al. (2012) A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control. Diabetes 61: 1263-1271.
19. Bhaskar V, Lau A, Goldfine ID, Narasimha AJ, Gross LM, et al. (2012) XMetA, an allosteric monoclonal antibody to the insulin receptor, improves glycaemic control in mice with diet-induced obesity. Diabetes Obes Metab.
20. Aitken R (2001) Methods in Molecular Biology. In: O'Brien PM, editor. Antibody phage display: methods and protocols. Totowa, NJ: Humana Press.
21. Barbas CF, Burton DR, Scott JK, Silverman GJ (2001) Phage Display: A Laboratory Manual. Plainview, NY: Cold Spring Harbor Laboratory Press.
22. Seino S, Bell GI (1989) Alternative splicing of human insulin receptor messenger RNA. Biochem Biophys Res Commun 159: 312-316. (Pubitemid 19087646)
23. Moller DE, Yokota A, Caro JF, Flier JS (1989) Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol 3: 1263-1269. (Pubitemid 19210437)
24. Zloza A, Sullivan YB, Connick E, Landay AL, Al-Harthi L (2003) CD8+ T cells that express CD4 on their surface (CD4dimCD8bright T cells) recognize an antigen-specific target, are detected in vivo, and can be productively infected by T-tropic HIV. Blood 102: 2156-2164. (Pubitemid 37122393)
25. Christopoulos A, Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54: 323-374. (Pubitemid 34575719)
26. Rathanaswami P, Babcook J, Gallo M (2008) High-affinity binding measurements of antibodies to cell-surface-expressed antigens. Anal Biochem 373: 52-60. (Pubitemid 350251324)
27. Xie L, Mark Jones R, Glass TR, Navoa R, Wang Y, et al. (2005) Measurement of the functional affinity constant of a monoclonal antibody for cell surface receptors using kinetic exclusion fluorescence immunoassay. J Immunol Methods 304: 1-14. (Pubitemid 41262216)
28. Ryan CJ, Zavodovskaya M, Youngren JF, Campbell M, Diamond M, et al. (2008) Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells. Prostate 68: 1232-1240.
29. Colquhoun D (2007) Why the Schild method is better than Schild realised. Trends Pharmacol Sci 28: 608-614.
30. Schild HO (1947) pA, a new scale for the measurement of drug antagonism. Br J Pharmacol Chemother 2: 189-206.
31. Maddux BA, See W, Lawrence JC Jr, Goldfine AL, Goldfine ID, et al. (2001) Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by mircomolar concentrations of alpha-lipoic acid. Diabetes 50: 404-410. (Pubitemid 32127299)
32. Surwit RS, Feinglos MN, Rodin J, Sutherland A, Petro AE, et al. (1995) Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 44: 645-651.
33. Arulmozhi DK, Kurian R, Bodhankar SL, Veeranjaneyulu A (2008) Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes. J Pharm Pharmacol 60: 1167-1173.
34. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, et al. (2008) The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 114: 23-37. (Pubitemid 351998752)
35. Conn PJ, Christopoulos A, Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8: 41-54.
36. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30: 586-623.
37. Sciacca L, Le Moli R, Vigneri R (2012) Insulin analogs and cancer. Front Endocrinol (Lausanne) 3: 21.
38. Vigneri R, Squatrito S, Frittitta L (2012) Selective insulin receptor modulators (SIRM): a new class of antidiabetes drugs? Diabetes 61: 984-985.
39. Morgan DO, Roth RA (1986) Mapping surface structures of the human insulin receptor with monoclonal antibodies: localization of main immunogenic regions to the receptor kinase domain. Biochemistry 25: 1364-1371. (Pubitemid 16048111)
40. Forsayeth JR, Caro JF, Sinha MK, Maddux BA, Goldfine ID (1987) Monoclonal antibodies to the human insulin receptor that activate glucose transport but not insulin receptor kinase activity. Proc Natl Acad Sci U S A 84: 3448-3451. (Pubitemid 17085421)
41. De Meyts P, Whittaker J (2002) Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 1: 769-783. (Pubitemid 37361561)
42. Smith BJ, Huang K, Kong G, Chan SJ, Nakagawa S, et al. (2010) Structural resolution of a tandem hormone-binding element in the insulin receptor and its implications for design of peptide agonists. Proc Natl Acad Sci U S A 107: 6771-6776.
43. Menting JG, Whittaker J, Margetts MB, Whittaker LJ, Kong GK, et al. (2013) How insulin engages its primary binding site on the insulin receptor. Nature 493: 241-245.
44. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, et al. (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49: 999-1005. (Pubitemid 30349423)
45. Kadowaki T, Bevins CL, Cama A, Ojamaa K, Marcus-Samuels B, et al. (1988) Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science 240: 787-790.
46. Taylor SI, Kadowaki T, Kadowaki H, Accili D, Cama A, et al. (1990) Mutations in insulin-receptor gene in insulin-resistant patients. Diabetes Care 13: 257-279. (Pubitemid 20092112)
47. Drejer K, Kruse V, Larsen UD, Hougaard P, Bjorn S, et al. (1991) Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 40: 1488-1495.
48. Hansen BF, Danielsen GM, Drejer K, Sorensen AR, Wiberg FC, et al. (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315 (Pt 1): 271-279. (Pubitemid 26113562)
49. Authier F, Di Guglielmo GM, Danielsen GM, Bergeron JJ (1998) Uptake and metabolic fate of [HisA8,HisB4,GluB10,HisB27]insulin in rat liver in vivo. Biochem J 332 (Pt 2): 421-430. (Pubitemid 28271874)
50. Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, et al. (2005) Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 54: 166-174. (Pubitemid 40105109)
51. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, et al. (1992) Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340: 925-929.
52. Chen YD, Jeng CY, Hollenbeck CB, Wu MS, Reaven GM (1988) Relationship between plasma glucose and insulin concentration, glucose production, and glucose disposal in normal subjects and patients with non-insulin-dependent diabetes. J Clin Invest 82: 21-25. (Pubitemid 18262493)
53. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR (1990) Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 113: 909-915.
54. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, et al. (1993) Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329: 1988-1992. (Pubitemid 24015042)
55. Defronzo RA (2009) Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58: 773-795.
56. (2011) National Diabetes Fact Sheet. CDC.
57. Kolterman OG, Gray RS, Griffin J, Burstein P, Insel J, et al. (1981) Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. J Clin Invest 68: 957-969. (Pubitemid 11023523)
58. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607.
59. Reaven GM, Olefsky JM (1978) The role of insulin resistance in the pathogenesis of diabetes mellitus. Adv Metab Disord 9: 313-331.